Modeling in pharmacoeconomic studies: funding sources and outcomes.
about
A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancerCost-effectiveness analysis for cliniciansCoauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysisA glimpse into the black box of cost-effectiveness analysesWhen are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.Reporting of funding sources and conflict of interest in the supportive and palliative oncology literature.The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidence.A critical systematic review of budget impact analyses on drugs in the EU countries.The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.Risk of bias in trial-based economic evaluations: identification of sources and bias-reducing strategies.Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval.Timely and complete publication of economic evaluations alongside randomized controlled trials.Cost-effectiveness of treatments for diabetic macular oedema: should we pay more attention to the appraisal and reporting of economic evaluations?To model or not to model: lessons from two vaccinations.Who should conduct modeling and cost-effectiveness analysis?Cholesterol-lowering drugs: science and marketing.Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?Do Financial Conflicts of Interest Bias Research?
P2860
Q27008869-C6BCFDFA-9529-4668-BEAA-280C7D950438Q34148072-2E890C1D-E973-457B-9730-7D3CA868F9ADQ34292774-ACD1DC7B-6ADB-4D89-AF8B-AC89A4D6D042Q34765208-DCEC3BCB-8082-4759-AA78-B564FAA95053Q34828582-C8A3B2E7-337C-436E-A96D-621036B6FC25Q37527158-D9E389F0-554F-4DE8-8247-8C2B51F41279Q38153808-6E3B63B4-9D16-4ECE-BDEA-A552059843C7Q38155481-88ECB7A3-BBFC-45B3-8F5F-BDDDC87262C2Q38165041-9A9EEC81-9BE4-4A82-9BF6-02957D1B8974Q38167294-AE4324F1-8434-4049-BA34-5933CB37131CQ38241647-FA235E38-21E9-45B3-998F-3A1A2BD2930DQ38786919-A16F602B-C36B-4803-9EDC-B4F991EAB86AQ39198395-62876ADF-0F6A-4048-A3A1-1E6F4C861D9DQ44139727-240B9BF8-279C-49A5-9075-7F0659B91076Q48221657-AEB532C5-9A0B-4F8E-BC10-FF3BA69940D8Q48703612-2F7E15A1-B252-4EE3-A4B1-17CB7A5C912CQ50690327-147BEA4A-1F7A-4AC9-9260-C56F950CD9DEQ51193262-33F750CE-F36A-4CB9-AE61-251C0C36B63FQ53195648-83A2B63D-ACFE-481B-BB7B-5115D4028F55Q56070330-4477F803-8E36-4E35-8591-10687BC83917
P2860
Modeling in pharmacoeconomic studies: funding sources and outcomes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Modeling in pharmacoeconomic studies: funding sources and outcomes.
@en
Modeling in pharmacoeconomic studies: funding sources and outcomes.
@nl
type
label
Modeling in pharmacoeconomic studies: funding sources and outcomes.
@en
Modeling in pharmacoeconomic studies: funding sources and outcomes.
@nl
prefLabel
Modeling in pharmacoeconomic studies: funding sources and outcomes.
@en
Modeling in pharmacoeconomic studies: funding sources and outcomes.
@nl
P2093
P2860
P1476
Modeling in pharmacoeconomic studies: funding sources and outcomes.
@en
P2093
Daniela Koleva
Gianluigi Casadei
Livio Garattini
P2860
P304
P356
10.1017/S0266462310000322
P577
2010-07-01T00:00:00Z